Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) insider Preston Klassen sold 31,445 shares of the stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $39,620.70. Following the sale, the insider now directly owns 36,055 shares in the company, valued at $45,429.30. This trade represents a 46.59 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Regulus Therapeutics Price Performance

NASDAQ RGLS traded up $0.05 during mid-day trading on Wednesday, hitting $1.27. The stock had a trading volume of 283,082 shares, compared to its average volume of 348,120. Regulus Therapeutics Inc. has a twelve month low of $1.08 and a twelve month high of $3.79. The firm's 50 day moving average is $1.53 and its 200 day moving average is $1.59. The stock has a market capitalization of $83.19 million, a price-to-earnings ratio of -1.19 and a beta of 1.60.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.18) by ($0.03). As a group, equities research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Planning acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the 3rd quarter worth $33,000. Jane Street Group LLC purchased a new position in shares of Regulus Therapeutics during the 3rd quarter worth $46,000. Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics during the 2nd quarter valued at about $136,000. Finally, JPMorgan Chase & Co. grew its holdings in shares of Regulus Therapeutics by 193.4% in the third quarter. JPMorgan Chase & Co. now owns 78,972 shares of the biopharmaceutical company's stock valued at $124,000 after purchasing an additional 52,059 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

RGLS has been the topic of several recent analyst reports. HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Monday, November 11th. StockNews.com raised shares of Regulus Therapeutics to a "sell" rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Regulus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $10.80.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.